Complivit Calcium D3

Active material: Calcium carbonate, Kolekaltsiferol
When ATH: A11AA04
CCF: Preparation, regulates the exchange of calcium and phosphorus
ICD-10 codes (testimony): E55, E58, M81.0, M81.1, M81.4, M81.8, M82
When CSF: 16.04.02
Manufacturer: OAO Pharmstandard-UfaVITA (Russia)

Pharmaceutical form, composition and packaging

◊ Chewable Tablets (orange) with rough porous surface, round, lenticular, from white to white with Valium a color shade of gray with splashes of color, with slight fruity odor.

Excipients: lactose, povidone (low molecular weight polyvinylpyrrolidone), potato starch, Croscarmellose sodium (vyvasol), lemon acid, Aspartame, magnesium stearate, orange flavor (powder).

* The composition of the granulate: butylhydroksytoluol, sucrose, gelatin, sodium aluminum silicate, medium-chain triglycerides, Modified starch, water.

30 PC. – plastic jars (1) – packs cardboard.
60 PC. – plastic jars (1) – packs cardboard.
90 PC. – plastic jars.
100 PC. – plastic jars.
120 PC. – plastic jars.

Pharmacological action

Combined preparation, action is due to its constituent components. Regulates calcium and phosphate, reduces bone resorption and increases bone density, compensates for the deficiency of calcium and kolekaltsiferola (vitamin D₃) body, increases calcium absorption in the intestine and reabsorption of phosphate in the kidneys, It promotes bone mineralization.

Calcium is involved in bone formation, blood coagulation, in maintaining a stable cardiac, in the implementation process of transmission of nerve impulses.

Kolekaltsiferol promotes calcium absorption in the intestine, formation and mineralization of bone and tooth tissue.

Use of calcium and prevents kolekaltsiferola increased production of parathyroid hormone, which is a stimulator of bone resorption increased.

Pharmacokinetics

Kolekaltsiferol absorbed from the small intestine.

Calcium absorbed in ionised form in the proximal part of the small intestine by active, vitamin D-dependent transport mechanism.

Testimony

- Prevention and complex therapy of osteoporosis (menopausal, senile, steroidal, idiopathic);

- Prevention and treatment of calcium deficiency and / or vitamin D₃.

Dosage regimen

The drug is taken orally, preferably during meals.

Adults in the treatment of osteoporosis appoint 1 tablet 2-3 times / day, for preventing osteoporosis - By 1 tablet 2 times / day.

At deficiency of calcium and vitamin D₃ adults and children over 12 years appoint 1 tablet 1-2 times / day; Children from 5 to 12 years - By 1-2 tablet per day; Children from 3 to 5 years the dose the doctor sets individually.

Tablets are chewed or swallowed whole.

Side effect

From the digestive system: dyspeptic reaction (constipation, flatulence, nausea, stomach ache, diarrhea).

Metabolism: hypercalcemia, hypercalciuria.

Other: allergic reactions.

Contraindications

- Hypercalcemia;

- Hypercalciuria;

- Calcium nefrourolitiaz;

- hypervitaminosis D;

- Decalcifying tumors (Myeloma, bone metastases, sarkoidoz);

- Osteoporosis, due to immobilization;

- Phenylketonuria (soderzhit aspartame);

- Pulmonary tuberculosis (active form);

- Chronic renal failure;

- Children up to age 3 years;

- Hypersensitivity to the drug.

Pregnancy and lactation

Precautions should use the drug during pregnancy and lactation (breast-feeding).

In pregnancy, the daily dose should not exceed 1500 mg calcium 600 ME of vitamin D₃.

Vitamin D and its metabolites are excreted in breast milk.

Overdose during pregnancy can lead to mental and physical development of the child.

Cautions

Komplyvyt^® Calcium D3 contains aspartame, which the body is transformed to phenylalanine, so the drug should not be administered to patients, PKU.

During the period of treatment is necessary to constantly monitor the excretion of calcium in the urine and the concentration of calcium and creatinine in the blood plasma. In the case of kaltsiurii, exceeding 7.5 mg / day (300 mg / day), necessary to reduce the dose or stop taking the drug.

Older people need calcium is 1500 mg / day, in kolekaltsiferola - 0.5-1000 IU / day.

To avoid overdose should take into account additional revenue from other sources kolekaltsiferola.

Overdose

Symptoms: thirst, polyuria, decreased appetite, nausea, vomiting, constipation, dizziness, weakness, headache, fainting, coma; prolonged use – calcification of blood vessels and tissues; laboratory parameters – hypercalciuria, hypercalcemia (plasma calcium by about 2.6 mmol).

Treatment: regidratatsiya, “loop” Diuretic, GCS, calcitonin, ʙisfosfonatы, restricted diet calcium, hemodialysis.

In case of symptoms of overdose the patient should seek medical advice.

Drug Interactions

Activity kolekaltsiferola may decrease when an application with phenytoin or barbiturates.

In case of simultaneous treatment of cardiac glycosides is necessary to monitor the ECG and clinical status, tk. calcium supplements may potentiate the therapeutic and toxic effects of cardiac glycosides.

Calcium and kolekaltsiferola can increase the absorption of tetracycline from the digestive tract. Therefore, the time interval between doses of drugs should not be less than 3 no.

To avoid reducing the absorption of drugs bisphosphonates or sodium fluoride, it is recommended to take Complivit^® Calcium D3 earliest, than two hours after their admission.

GCS reduces the absorption of, so the treatment of corticosteroids may need to increase the dose Complivit^® Calcium D3.

Simultaneous treatment with cholestyramine or laxatives based on mineral or vegetable oil may reduce the absorption kolekaltsiferola.

With simultaneous use of thiazide diuretics increases the risk of hypercalcemia, tk. they increase the tubular reabsorption of calcium. Furosemide and other “loop” Diuretic, conversely, increase the excretion of calcium by the kidneys.

Conditions of supply of pharmacies

The drug is resolved to application as an agent Valium holidays.

Conditions and terms

The drug should be stored out of reach of children, dry, dark place at a temperature no higher than 25 ° C. Shelf life – 2 year.